Michael Nedelcovych, an analyst from TD Cowen, maintained the Buy rating on Takeda Pharmaceutical Company (TAK – Research Report). The associated price target is $16.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Michael Nedelcovych has given his Buy rating due to a combination of factors influencing Takeda Pharmaceutical Company’s outlook. The company has demonstrated resilience in the face of potential risks, such as the MFN and IRA pricing negotiations, which could impact the pricing of their key drug, Entyvio. Despite these challenges, Takeda maintains a strong sales ambition for Entyvio, forecasting peak sales between $7.5 billion and $9 billion.
Furthermore, Takeda’s management has expressed confidence in the continued growth of Entyvio, noting its faster-than-market growth trajectory and the preference of patients for the subcutaneous version. Additionally, the company’s minimal exposure to tariffs and the relatively minor impact of FDA disruptions further support the positive outlook. These factors, combined with promising data anticipated for other key drugs, contribute to the Buy rating.
Nedelcovych covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Coherus Biosciences, and Molecular Partners AG. According to TipRanks, Nedelcovych has an average return of -16.7% and a 34.29% success rate on recommended stocks.